The Free Lunch Is Over, Except Now It’s Not: What Near-Zero Software Costs Mean for Every Player in Healthcare

Why It Matters

The rapid commoditization of software removes a key barrier to entry, forcing incumbents to compete on data and relationships rather than code, and accelerating consolidation across the healthcare value chain.

Key Takeaways

• AI coding cuts healthcare software costs up to 90%
• Hospitals can rebuild EHR modules internally, challenging vendors
• Payers can internalize prior‑auth engines at fraction cost
• Pharma's trial platforms become commoditized, data becomes moat
• Vendors relying on proprietary code face existential risk

Pulse Analysis

The emergence of agentic coding platforms such as GitHub Copilot, Cursor, and Devin is redefining the economics of software creation in health care. By automating routine coding tasks and accelerating development cycles, these tools compress timelines from months to days and slash budgets by up to ninety percent. The analogy to the electrification of industry is apt: just as the power grid turned electricity into a utility, AI coding is turning software into a commodity input, especially for rule‑based applications that dominate the health‑tech landscape.

For hospitals and health systems, the new reality means internal IT teams can once again become credible builders of care‑management, population‑health, and interoperability solutions, directly challenging entrenched EHR giants and middleware providers. Payers stand to internalize prior‑authorization, claims adjudication, and utilization‑management engines, reducing reliance on third‑party point solutions and driving cost efficiencies. In pharma, platforms for clinical‑trial management, regulatory submissions, and commercial analytics are losing their differentiation, shifting competitive advantage to proprietary data assets and established therapeutic relationships. Vendors whose sole defensibility was the difficulty of rebuilding their software now face a stark existential threat.

Investors should recalibrate their theses toward companies that leverage unique data, deep clinical workflow integration, and regulatory expertise—moats that AI coding cannot replicate. Funding models that prioritize open‑source or low‑code development will likely see higher churn, while firms that embed AI‑enhanced analytics into proprietary datasets can capture new value. Over the next two years, the market will reward those who anticipate the commoditization of code and double down on data‑centric strategies, reshaping the competitive hierarchy across the entire health‑care ecosystem.